Fucosylation of antibodies in multi-inflammatory syndrome in children after SARS-CoV-2 infectio

Recruiting

• Conditions: 10024970; Covid; inflammatory disease; 10003816; 10047438

• Registration Number: NL-OMON54254
• Lead Sponsor: niversitair Medisch Centrum Utrecht

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 9 April 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 120

Inclusion Criteria

Children 0-16 years of age with a laboratory confirmed COVID-19 (RIVM) and
MIS-C.

Exclusion Criteria

Severe immune-related comorbidity (humoral immunodeficiency, cellular
immunodeficiency, treatment for cancer, treatment with biologicals, IVIG
treatment at moment of inclusion).

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Fucosylation of SARS-CoV-2 IgG antibodies defined as percentage of<br /><br>fucose-containing glycans attached to N297 in the IgG-Fc. Focus will be on the<br /><br>main subclass generated (IgG1 and IgG3). </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>We compare the anti-CoV antibody response and interaction with immune receptors<br /><br>between cases and controls by:<br /><br>- Anti-CoV antibody levels, (sub)class and antigen specificity (ELISA)<br /><br>- Anti-CoV antibody glycosylation<br /><br>- Interaction of serum-derived patient anti-CoV antibodies with a biosensor<br /><br>equipped with all human Fc-gamma receptors<br /><br>- Inflammatory markers of juvenile idiopathic arthritis (see UCAN CAN-DU<br /><br>protocol)<br /><br>-To study gene expression profiles to distinguish between inflammatory and<br /><br>infectious causes of fever.</p><br>